XXXX due to @entity99 : a case report.

@entity1 @entity1375 @entity99 @entity409 @entity1955 @entity2016 @entity6145 @entity6750 @entity8146 @entity617 @entity1374
Although @entity8146 ( @entity8146 ) is a commonly encountered @entity99 during infancy, @entity8146 -related @entity1375 is rare. We present a @entity1 who developed @entity8146 -related @entity1375 during the neonatal period and showed marked improvement in @entity1375 by regression of @entity8146 . A 28-day-old @entity1 with TSH level of 77 mIU/mL on neonatal screening and diagnosed as @entity6750 was started on @entity1955 ( @entity2016 ) (11  g/kg/day) therapy on the 21(th) day of life. On physical examination, the liver was palpable 5 cm below the right costal margin, and the thyroid gland was nonpalpable. Thyroid ultrasonography was normal. Although @entity2016 dose was increased to 15  g/kg/day, TSH was not suppressed and free T3 level remained low. @entity409 was detected by abdominal ultrasonography and magnetic resonance imaging. Treatment was started with @entity617 2 mg/kg/day and alpha-interferon 3 million U/m(2)/3 times per week. @entity1374 was thought to be due to type 3 iodothyronine deiodinase activity expressed by @entity8146 . @entity2016 therapy was changed to Bitiron   tablet, which includes both T4 and T3, and euthyroidism was attained within 1 month. Thyroid hormone requirement was reduced and treatment was discontinued after regression of the @entity8146 . At the most recent visit, the @entity1 was 21 months old and off treatment. His growth and neurological development were normal for age and he was euthyroid. @entity8146 should be considered in cases with @entity1375 resistant to high-dose @entity6145 replacement. The treatment of @entity8146 in combination with T4 and T3 therapy results in euthyroidism.
